Candidate for Third-line or Subsequent Lines of Therapy, Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
Conditions
Keywords
colorectal cancer
Brief summary
COPERNIC is an international, multicentre, single-arm study. Chemo-refractory mCRC subjects who meet all eligibility criteria will be treated with standard systemic chemotherapy (the decision about the treatment regimen being made by the treating physician) and undergo tumour assessment by standard imaging (either CT scan or MRI scan) at baseline and every 8 or 12 weeks until evidence of tumour progression. Response to treatment will be assessed by the local investigators according to the RECIST criteria version 1.1. Blinded, independent central review of the imaging scan will be carried out, this having no impact on treatment decisions thatwhich will remain the prerogative of the treating physician. Serial blood samples from study subjects will be collected at pre-defined time points for ctDNA testing. Also, archived tumour tissue from each subject will be collected. Prospective and retrospective ctDNA analyses on blood samples will be carried out, and dynamics of ctDNA will be correlated with treatment outcomes prognosis.
Detailed description
COPERNIC is an international, multicentre, single-arm study. Chemo-refractory mCRC subjects who meet all eligibility criteria will be treated with standard systemic chemotherapy (the decision about the treatment regimen being made by the treating physician) and undergo tumour assessment by standard imaging (either CT scan or MRI scan) at baseline and every 8 or 12 weeks until evidence of tumour progression. Response to treatment will be assessed by the local investigators according to the RECIST criteria version 1.1. Blinded, independent central review of the imaging scan will be carried out, this having no impact on treatment decisions which will remain the prerogative of the treating physician. Serial blood samples from study subjects will be collected at pre-defined time points for ctDNA testing. Also, archived tumour tissue from each subject will be collected. Prospective and retrospective ctDNA analyses on blood samples will be carried out, and dynamics of ctDNA will be correlated with prognosis. Two ctDNA assays will be used in this study: * FoundationOne Liquid CDx (F1LCDx) for comprehensive genomic profile (CGP) assessment * F1Monitor for monitoring purpose For subjects receiving treatments with a 2- or 4-weekly schedule, blood and plasma samples for ctDNA testing will be collected at the following timepoints: Blood : * Before treatment start (day 1) * 2 weeks after treatment start (day 15) Plasma : * Before the treatment start (day 1) * 4 weeks after treatment start (day 29) * 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1 For subjects receiving treatments with a 3-weekly schedule, blood and plasma samples for ctDNA testing will be collected at the following timepoints: Blood : * Before treatment start (day 1) * 3 weeks after treatment start (day 22) Plasma : * Before treatment start (day 1) * 6 weeks after treatment start (day 43) * 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1 ctDNA analyses will be done in a centralised laboratory (Foundation Medicine Inc). Full report of the ctDNA analysis will be provided to the study team to allow correlation with clinical data and exploratory analyses. The results of the ctDNA analysis will not be communicated to the treating physician (with the only exception of the analysis by F1CDx on tumour tissue at screening) and therefore will not have any impact on treatment decision (i.e., all study subjects will be treated according to standard practice).
Interventions
OTHERBlood Sample Collection
For subjects receiving treatments with a 2- or 4-weekly schedule, samples for ctDNA testing will be collected at the following timepoints: Blood : * Before treatment start (day 1) * 2 weeks after treatment start (day 15) Plasma : * Before the treatment start (day 1) * 4 weeks after treatment start (day 29) * 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1 For subjects receiving treatments with a 3-weekly schedule, samples for ctDNA testing will be collected at the following timepoints: Blood : * Before treatment start (day 1) * 3 weeks after treatment start (day 22) Plasma : * Before treatment start (day 1) * 6 weeks after treatment start (day 43) * 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1
Sponsors
Jules Bordet Institute
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old 2. Male or female 3. ECOG performance status ≤2 4. Must have histologically or cytologically verified colorectal cancer adenocarcinoma 5. Inoperable locally advanced or metastatic disease 6. Presence of measurable disease (by RECIST criteria version 1.1) on baseline CT scan of the thorax/abdomen/pelvis or CT scan of the thorax and MRI of the abdomen/pelvis 7. At least two prior systemic treatments for advanced/metastatic colorectal cancer including oxaliplatin and irinotecan-based therapy (adjuvant or neoadjuvant systemic chemotherapy will be considered if tumour progression was documented within 6 month of the last chemotherapy dose) 8. Candidate for standard third-line or subsequent lines of therapy as per decision of the treating physician 9. Life expectancy of at least 3 months 10. Women of childbearing potential must have a negative serum pregnancy test done within 28 days prior to enrolment. 11. Effective contraception is in place for women of childbearing potential. 12. Completion of all necessary screening procedures within 28 days prior to enrolment. 13. Availability of archived tumour tissue 14. Signed Informed Consent form (ICF) obtained prior to any study related procedure. Inclusion criterion applicable to FRANCE only 15. Affiliated to the French Social Security System
Exclusion criteria
1. Tumours other than colorectal cancer 2. Histologies other than adenocarcinoma 3. Any baseline medical condition that would contraindicate the use of systemic chemotherapy or may preclude the regular administration of the same 4. Any psychiatric condition that would prohibit the understanding or rendering of informed consent 5. Other invasive malignancy within 3 years except for non-invasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured 6. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study. 7. Pregnant and/ or lactating women Exclusion criterion applicable to FRANCE only 8. Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal timepoint and cut-off value for early on-treatment ctDNA changes | at 2 or 3 weeks | To select the optimal timepoint and cut-off value for early on-treatment ctDNA changes (as assessed by F1Monitor) that predict progressive disease as best radiological response with a high degree of specificity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| optimal timepoint and cut-off value for on-treatment ctDNA changes at 4 or 6 weeks | Day 29 or 43 | To select the optimal timepoint and cut-off value for on-treatment ctDNA changes at 4 or 6 weeks (as assessed by F1Monitor) that predict progressive disease as best radiological response with a high degree of specificity. |
| rapid turnaround time of ctDNA testing based on F1LCDx | through study completion, an average of 1 year | To demonstrate rapid turnaround time of ctDNA testing based on F1LCDx and identify technical or logistical challenges to the implementation of an on-treatment ctDNA-driven treatment approach in a follow-on study. |
| tumour heterogeneity | Day 1 | To evaluate tumour heterogeneity before treatment start as assessed by F1CDx in the tumour tissue and F1LCDx in the whole blood. |
| CGP changes during treatment | Day 1 and 15 or D1 and D22 | To track CGP changes during treatment as assessed by F1LCDx. |
Countries
Belgium, France
Outcome results
None listed